<DOC>
	<DOCNO>NCT00070382</DOCNO>
	<brief_summary>RATIONALE : Darbepoetin alfa epoetin alfa may stimulate red blood cell production treat anemia patient receive chemotherapy . It yet know whether darbepoetin alfa effective epoetin alfa treat patient anemia . PURPOSE : Randomized phase III trial compare effectiveness darbepoetin alfa epoetin alfa treat anemia patient receive chemotherapy cancer .</brief_summary>
	<brief_title>Darbepoetin Alfa Compared With Epoetin Alfa Treating Anemia Patients Receiving Chemotherapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy darbepoetin alfa v epoetin alfa anemia patient non-myeloid malignancy receive chemotherapy . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord screen hemoglobin concentration ( le 10.0 g/dL v 10.0-11.0 g/dL ) type concurrent chemotherapy ( platinum-based v non-platinum-based ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive darbepoetin alfa subcutaneously ( SC ) every week 12 week ( i.e. , week 1 , 3 , 5 , 7 , 9 , 11 ) . - Arm II : Patients receive epoetin alfa SC weekly 12 week . Patients follow 1 3 week . PROJECTED ACCRUAL : A total 600 patient ( 300 per treatment arm ) accrue study within 6 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Diagnosis nonmyeloid malignancy Currently receive plan receive least 8 week cyclic cytotoxic chemotherapy Hemoglobin great 11.0 g/dL 18 ECOG 02 Bilirubin less 2 time upper limit normal ( ULN ) Creatinine le 2 time ULN Negative pregnancy test Fertile patient must use effective contraception HIV negative More 30 day since prior darbepoetin alfa epoetin alfa More 30 day since prior participation investigational device drug trials The following diagnosis exclude : Acute myeloid leukemia Chronic myeloid leukemia Acute lymphoblastic leukemia Hairy cell leukemia Burkitt 's lymphoma Lymphoblastic lymphoma primary hematologic disorder would cause anemia ( e.g. , sickle cell anemia ) angina congestive heart failure New York Heart Association class III IV heart disease hypertension cardiac arrhythmia unstable uncontrolled disease condition would affect cardiac function pregnant nursing know seizure disorder know sensitivity study agent clinically significant inflammatory disease ( e.g. , rheumatoid arthritis Crohn 's disease ) confirm neutralizing antibody epoetin alfa disorder would preclude study compliance give informed consent concurrent epoetin alfas prior randomization study concurrent investigational agent procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
</DOC>